Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Naoko Edo"'
Autor:
Akiko Watanabe, Naoki Miyoshi, Yusuke Ito, Aya Isobe, Naoko Edo, Yoshiyuki Morishima, Kyoji Yamaguchi, Kengo Noguchi
Publikováno v:
Thrombosis research. 168
An activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates fibrinolysis by removing C-terminal lysine/arginine residues from partially degraded fibrin. We have identified a novel low-molecular-weight inhibitor of TAFIa, DS-1040, to b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7da460777329c2e20492ca7a2c46bc88
https://pubmed.ncbi.nlm.nih.gov/29957475
https://pubmed.ncbi.nlm.nih.gov/29957475
Publikováno v:
Stroke. 47
Introduction: DS-1040 is a novel inhibitor of the activated thrombin-activatable fibrinolysis inhibitor (TAFIa) and is in clinical development for the treatment of acute ischemic stroke. The objectives of this study were to establish a tissue plasmin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f01cb62eae8cfd7c4f138fc69aaec33
https://doi.org/10.1161/str.47.suppl_1.tp283
https://doi.org/10.1161/str.47.suppl_1.tp283
Abstract TP271: Improvement of Cerebral Blood Flow With DS-1040 in a Rat Thromboembolic Stroke Model
Publikováno v:
Stroke. 47
Introduction: DS-1040 is a novel inhibitor of the activated thrombin-activatable fibrinolysis inhibitor (TAFIa) and is in clinical development for the treatment of acute ischemic stroke (AIS). The objective of this study was to investigate the effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2f631bb13676058dd21f4ffcae2dabf
https://doi.org/10.1161/str.47.suppl_1.tp271
https://doi.org/10.1161/str.47.suppl_1.tp271
Publikováno v:
Brain Research. 1021:159-166
The study of biomarkers associated with stroke has proved to be of considerable utility. The astroglial protein S-100b is a candidate marker for cerebral tissue damage. We used a rat embolic model produced by injection of microspheres to demonstrate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b57cfb7e5665bc453812df9a882a37c
https://doi.org/10.1016/j.brainres.2004.06.012
https://doi.org/10.1016/j.brainres.2004.06.012
Autor:
Chikako Kamisato, Yoshiyuki Morishima, Naoko Edo, Toshiro Shibano, Yuko Honda, Akemi Kita, Naoki Tsuji
Publikováno v:
Thrombosis research. 130(3)
Introduction Factor Xa (FXa) is a key serine protease in the coagulation cascade and a promising target for a new antithrombotic agent. Edoxaban is an oral, selective and direct FXa inhibitor. The objective of this study was to compare the antithromb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::914bdbbb0dba21fbdffc4681dc5e8c4d
https://pubmed.ncbi.nlm.nih.gov/22647432
https://pubmed.ncbi.nlm.nih.gov/22647432